If you have been reading about Reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-09. Numbers and descriptions here follow the published literature rather than marketing material.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
== Dalton's chemical atomism == In 1804, John Dalton studied data gathered by himself and by other scientists and noticed a pattern that later came to be known as the law of multiple proportions: in compounds which contain two particular elements, the amount of Element A per measure of Element B will differ across these compounds by ratios of small whole numbers. For instance, Dalton investigated three oxides of nitrogen: "nitrous oxide", "nitrous gas", and "nitric acid". These compounds are known today as nitrous oxide, nitric oxide, and nitrogen dioxide respectively. "Nitrous oxide" is 63.3% nitrogen and 36.7% oxygen, which means it has 80 g of oxygen for every 140 g of nitrogen. "Nitrous gas" is 44.05% nitrogen and 55.95% oxygen, which means there are 160 g of oxygen for every 140 g of nitrogen. "Nitric acid" is 29.5% nitrogen and 70.5% oxygen, which means it has 320 g of oxygen for every 140 g of nitrogen. 80, 160, and 320 form a ratio of 1:2:4.
is used to control the proportion of amino acids that are unchanged. By using only alignments of proteins that had at least 85% similarity, it could be reasonably assumed that the mutations observed were direct, without any intermediate states. This means that scaling down these counts by a common factor would provide an accurate estimate of the mutation counts had the similarity been closer to 100%. It also means that the number of mutations per 100 amino acids, the
=== Familia Presto series 1 (FA3; 1970) === From April 1970, the Presto nameplate was added into the entire Familia range, "Presto" means "quick" in Italian. Brand new overhead camshaft 1.3-litre TC engine also appeared, derived from the smaller 1.0-litre OHC engine already seen in the first generation Familia coupé. At the same time, the range received a light facelift including a chrome strip around the front grille. Unlike the pickup, the vans also used the "Familia Presto" name. Chassis codes are SPCV for the 1.0-litre and STBV for the 1.3-litre model, with power outputs as for the saloon/coupé. Standard and Deluxe versions were available, with the Deluxe also offering five-door bodywork. The Familia was exported as the "Mazda 1300", and replaced the previous generation 1200 model in most markets. In Finland, the Familia Presto was marketed as the "Mazda Marella." The saloon and coupé were updated in 1972 in Japan and in the autumn of 1973 for export market, but the pickup and wagon/van versions continued with little change. The vans and pickups actually soldiered on until 1978, by which time a wagon version of the succeeding FA4 Familia (323/GLC) had been introduced. The later pickup versions were also available in a long-wheelbase version, and still featured an 85 PS (63 kW) (SAE gross) version of the 1.3-litre TC engine, unaffected by the tighter Japanese emissions standards for passenger cars. The "1200" was offered in the United States in 1971 and again for the 1973 model year.
In veterinary practice, dogs are the species most commonly affected by hypothyroidism. The majority of cases occur as a result of primary hypothyroidism, of which two types are recognized: lymphocytic thyroiditis, which is probably immune-driven and leads to destruction and fibrosis of the thyroid gland, and idiopathic atrophy, which leads to the gradual replacement of the gland by fatty tissue. There is often lethargy, cold intolerance, exercise intolerance, and weight gain. Skin changes and fertility problems are seen in dogs with hypothyroidism, as well as many other symptoms. The signs of myxedema can be seen in dogs, with prominence of skin folds on the forehead, and cases of myxedema coma are encountered. The diagnosis can be confirmed by a blood test, as the clinical impression alone may lead to overdiagnosis. Lymphocytic thyroiditis is associated with detectable antibodies against thyroglobulin, although they typically become undetectable in advanced disease. Treatment is with thyroid hormone replacement. Other species that are less commonly affected include cats and horses, as well as other large domestic animals. In cats, hypothyroidism is usually the result of other medical treatments such as surgery or radiation. In young horses, congenital hypothyroidism has been reported predominantly in Western Canada and has been linked with the mother's diet.
In addition, examination of minor events in first heat thermal analysis data can be useful as these apparently "anomalous peaks" can in fact also be representative of process or storage thermal history of the material or polymer physical aging. Comparison of first and second heat data collected at consistent heating rates can allow the analyst to learn about both polymer processing history and material properties.
Sources: en.wikipedia.org
=== Wound healing === Research on novel drug formulations for the delivery of doxycycline in wound treatment is expanding, focusing on overcoming stability limitations for long-term storage and developing consumer-friendly, parenteral antibiotic delivery systems. The most common and practical form of doxycycline delivery is through wound dressings, which have evolved from mono- to three-layered systems to maximize healing effectiveness. Research directions on the use of doxycycline in wound healing include the continuous stabilization of doxycycline, scaling up technology and industrial production, and exploring non-contact wound treatment methods like sprays and aerosols for use in emergencies and when medical care is not readily accessible.
=== Recreational use === As a μ-opioid agonist, tianeptine in large doses has high abuse potential. In 2001, Singapore's Ministry of Health restricted tianeptine prescribing to psychiatrists due to its recreational potential. Between 1989 and 2004, in France 141 cases of recreational use were identified, correlating to an incidence of 1 to 3 cases per 1000 persons treated with tianeptine and 45 between 2006 and 2011. According to Servier, stopping of treatment with tianeptine is difficult, due to the possibility of withdrawal symptoms. The severity of the withdrawal is dependent on the daily dose, with high doses being extremely difficult to quit. An official DEA statement states that the withdrawal symptoms in humans typically result in: agitation, nausea, vomiting, tachycardia, hypertension, diarrhea, tremor, and diaphoresis, similar to other opioid drugs. In 2007, according to French Health Products Safety Agency, tianeptine's manufacturer Servier agreed to modify the drug's label, following problems with dependency. Tianeptine has been intravenously injected by drug users in Russia. This method of administration reportedly causes an opioid-like effect and is sometimes used in an attempt to lessen opioid withdrawal symptoms. Tianeptine tablets contain silica and do not dissolve completely. Often the solution is not filtered well thus particles in the injected fluid block capillaries, leading to thrombosis and then severe necrosis.
From about 1989 to 2018, Ontario has reported a deficit almost every year; the province's net debt increased to approximately $311.6 billion (by October 2018); and Ontario's net debt‐to‐GDP ratio grew from 13.4% to about 40.5% in 2018–19. According to an April 11, 2018 Royal Bank of Canada (RBC) report, which was based on figures provided by the Ford government, the revised estimate of Ontario's deficit was $11.7 billion in 2018–2019 and it was projected to decrease by $1.4 billion in 2019–2020 mainly because of "the removal of the $1 billion contingency reserve." At that time, it was projected that the deficit would be "completely eliminated in 2023–2024 with a small surplus of $0.3 billion." By October 2019, the Financial Accountability Officer, Weltman, said that the FAO had been in error when they—and the Ford government—had projected a $11.7-billion deficit that was reported in the spring 2019 budget. By June 2018, Ontario had "Canada's second-highest public debt per person and a growing budget deficit", according to The Economist. In October 2018, the Ontario Finance Department reported that Ontario's public debt per person, at $23,014, had surpassed that of Quebec at $21,606 in the fiscal year 2017–2018. Newfoundland and Labrador's public debt per capita, at $27,761, was the highest in Canada. By 2019, the Ontario Chamber of Commerce reported that Ontario's debt was over $348 billion—representing about 41% of provincial GDP of almost $850 billion. Ontario's GDP is much larger than any of the other provinces and is almost half of Canada's GDP.
== Method principle == Before the introduction of the first automated cell counters, hematologists were referred to manual cell count under the microscope. The Celloscope method for automated counting of blood cells was described in an article by Öhlin in 1958. In the described method, cells in a saline (conductive) solution are allowed to pass through a capillary with a length and diameter corresponding to the size of blood cells. At the same time, an electric current passes the capillary, and each cell then gives rise to an electric pulse through the increase in resistance that it causes in the electric circuit. The number of pulses is recorded and corresponds to the number of cells in a certain volume. Diluting the blood sample to a sufficient extent for the distance between the cells when passing through the capillary to be greater than the dimension of the cells and capillary ensures that each cell is counted individually. As cells are counted in an absolute volume of the suspension, the number of cells in mm3 of whole blood can be calculated using the dilution factor. The described automated Celloscope cell count method enabled an improved accuracy compared with manual examination by microscopy, while decreasing manual work for the operator. The method allows 50 000 cells to be counted in about 45 seconds, with high accuracy. The Celloscope counter was also equipped with a discriminator, or electrical threshold, which allows only pulses above a certain size to be counted, enabling different blood cells to be counted.
Sources: en.wikipedia.org
From clinical trials, only 14% of heart attacks occur from artery closure at plaques producing 75% or greater stenosis before the vessel closing. If the fibrous cap separating a soft atheroma from the bloodstream within the artery ruptures, tissue fragments are exposed and released. These tissue fragments are very clot-promoting, containing collagen and tissue factor; they activate platelets and activate the system of coagulation. The result is the formation of a thrombus (blood clot) overlying the atheroma, which obstructs blood flow acutely. With the obstruction of blood flow, downstream tissues are starved of oxygen and nutrients. If this is the myocardium (heart muscle) angina (cardiac chest pain) or myocardial infarction (heart attack) develops.
== Osteogenesis == Bone is formed by one of two processes: endochondral ossification or intramembranous ossification. Endochondral ossification is the process of forming bone from cartilage and this is the usual method. This form of bone development is the more complex form: it follows the formation of a first skeleton of cartilage made by chondrocytes, which is then removed and replaced by bone, made by osteoblasts. Intramembranous ossification is the direct ossification of mesenchyme as happens during the formation of the membrane bones of the skull and others. During osteoblast differentiation, the developing progenitor cells express the regulatory transcription factor Cbfa1/Runx2. A second required transcription factor is Sp7 transcription factor. Osteochondroprogenitor cells differentiate under the influence of growth factors, although isolated mesenchymal stem cells in tissue culture may also form osteoblasts under permissive conditions that include vitamin C and substrates for alkaline phosphatase, a key enzyme that provides high concentrations of phosphate at the mineral deposition site. In turn osteoblasts may give rise to osteocytes in a process dependent on the vascular musculature of blood vessels in the bone.
Vascular EDS (vEDS; formerly categorized as type 4) is identified by skin that is thin, translucent, extremely fragile, and bruises easily. It is also characterized by fragile blood vessels and organs that can easily rupture. Affected people are frequently short and have thin scalp hair. It also has characteristic facial features, including large eyes, an undersized chin, sunken cheeks, a thin nose and lips, and ears without lobes. Joint hypermobility is present, but generally confined to the small joints (fingers, toes). Other common features include club foot, tendon and/or muscle rupture, acrogeria (premature aging of the skin of the hands and feet), early-onset varicose veins, pneumothorax (collapse of a lung), the recession of the gums, and a decreased amount of fat under the skin. It can be caused by the variations in the COL3A1 gene. Rarely, COL1A1 variations can also cause it.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.